Serum Pentraxin-3 Research Articles

Exploratory study on reference intervals of calprotectin and pentraxin 3.

The aim of our study was to determine reference intervals for serum pentraxin 3 and calprotectin, as well as for urine calprotectin according to the CLSI EP28-A3C guidelines for defining, establishing, and verifying reference intervals in the clinical laboratory. A total of 120 serum and urine samples from either healthy volunteers or outpatients were used for reference interval establishment. The participants had CRP levels, leucocyte counts, serum urea levels, creatinine levels, and estimated glomerular filtration rates (CKD-EPI eGFRs) within the reference range and no medical history of acute/chronic inflammatory diseases/conditions or cancer. Calprotectin was measured via a commercially available turbidimetric method - the Bühhlmann fCAL® Turbo Reagent Kit - while pentraxin 3 was measured using the Human Pentraxin 3 ELISA Kit from the BioVendor Group. The serum calprotectin reference range was ≤3.6mg/L, the 90% CI for the upper reference range was 3.1-4.1mg/L, while the serum pentraxin 3 reference concentration was ≤3.0µg/L, and the 90% CI for the upper reference range being 2.7-3.2µg/L. Additionally, the urinary calprotectin concentration was ≤1.4mg/L, with a 90% CI for the upper reference range of 1.0-1.7mg/L. This study reports sample and method-specific reference intervals for the detection of various inflammatory conditions.

Serum pentraxin-3 expression varies according to polycystic ovary syndrome phenotypes.

Pentraxin-3 (PTX-3) is a multibiological protein involved in cumulus cell expansion, fertilization, and implantation. This study was designed to analyze how circulating PTX-3 levels change in women with polycystic ovary syndrome (PCOS). A total of 50 Turkish participants, 35 of whom had PCOS and 15 of whom were fertile, were included in the study. Patients in the PCOS group were divided into 4 different phenotypes according to the NIH criteria (phenotypes A-D). The number of patients in phenotype A was the highest 13 (37.1%). In the calculations made without phenotyping, the serum ptx3 levels of the PCOS group were found to be significantly lower compared to the fertile control group (3.32 ± 0.73 ng/mL vs 4.97 ± 1.29 ng/mL; P < .001). The ptx3 value of phenotypes A and B was significantly lower than phenotype D (P = .008 and P = .009, respectively). When the phenotypes were compared with the fertile control group, the PTX-3 levels of phenotypes A and B were significantly lower than the fertile group. Although the ptx3 levels of phenotypes C and D were lower than the fertile group, the difference did not reach statistical significance. This is the first study to investigate serum ptx3 levels by phenotype in PCOS. While serum PTX-3 levels decreased in phenotypes A and B, ptx3 levels in phenotypes C and D were similar in fertile patients.

Pentraxin-3 is a novel marker for the diagnosis of endometriosis

Introduction: Endometriosis is one of the most common reproductive disorders affecting women. The pathophysiology of endometriosis is also quite complicated, and many mechanisms have been put forward. Pentraxin-3 is a glycoprotein released by leukocyte and myeloid dendritic cells in peripheral blood with the stimulation of some cytokines, especially IL-1 and TNF-α, Toll-Like Receptor agonists, or microbial components. It has been shown that pentraxin-3 is also released from ectopic endometrial cells. The aim of this study is to investigate serum pentraxin-3 levels and their correlation with endometriosis in women with endometriosis and healthy women without endometriosis. Methods: This case-control study evaluated patients diagnosed with endometriosis based on imaging techniques or laparoscopy between 2018 and 2020. Serum samples of 71 patients who had been diagnosed with endometriosis as a case group and 56 healthy patients who had undergone laparoscopic tubal ligation and were proven to be endometriosis-free as a control group were compared for pentraxin-3 level. Results: Serum pentraxin-3 level was significantly higher in the endometriosis group compared with the control group ( p &lt; 0.05). Parity and gravida were significantly higher in the control group than in the endometriosis group. When patients with endometriosis surgery history were excluded, there was no significant change in serum pentraxin-3 levels in patients with medical treatment for endometriosis ( p &gt; 0.05). Both the sensitivity and specificity of serum pentraxin-3 were 73.2%. Conclusions: These results demonstrate a relationship between serum pentraxin-3 and endometriosis. Serum pentraxin-3 might be used as a non-invasive method for the diagnosis of endometriosis.

Serum Pentraxin 3 Level in Egyptian Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes

Abstract Background Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver injury and is strongly associated with type 2 diabetes mellitus (T2DM). Pentraxin 3 (PTX3) is an acute‑phase reactant and an essential component of innate immunity. Plasma PTX3 level is, according to some data, a marker for NAFLD. We aimed to assess the value of serum Pentraxin 3 level as a non-invasive bio-marker of NAFLD in patients with Type II DM. Methods This case-control study included 96 subjects classified in to 32 patients with T2DM and NAFLD, 32 patients with T2DM and without NAFLD, and 32 healthy subjects. All studied subjects underwent a detailed clinical examination, laboratory tests, abdominal ultrasound, Fatty liver index score, and calculated serum Pentraxin. Results Serum Pentraxin demonstrated a high statistically significant correlation with the presence of NAFLD in patients with Type II DM and in healthy people. Conclusion Pentraxin 3 is a sensitive, specific, and a promising biomarker for detection of liver injury in NAFLD when suspected in patients with and without DM.

Assessment of Serum Pentraxin 3 Level in Critically Ill Pediatric Patients with COVID 19 Infection and Multisystem Inflammatory Syndrome in Children (MIS-C) Related to COVID 19

Abstract Background Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but severe condition that has been observed in pediatric patients following COVID-19 infection. The identification of prognostic markers for MIS-C is crucial for early detection and appropriate management. Two potential prognostic markers that have been studied in relation to MIS-C are pentraxin 3 (PTX3) and procalcitonin. Aim To assess serum Pentraxin 3 level in COVID-19 infection pediatric patients and Multisystem Inflammatory Syndrome in Children (MIS-C) related to COVID-19. Methods This is a cohort study consisting of (75) children, joined through consecutive method. They were assigned into 3 groups, pediatric patients with COVID-19, Pediatric patients with MIS-C related to COVID-19, as well as healthy controls matching age and gender in both groups. In addition, patients were mainly assessed for serum Pentraxin 3, and Serum Procalcitonin levels by ELISA. Results we included 28 patients in the Covid-19 group, and 29 patients in the MIS-C group with median age of 31.5 months, and 84 months, respectively. We found that the median Pentraxin 3 (PTX3), and Procalcitonin (PCT) levels were significantly higher in the Covid 19 group than the MISC and control groups with values of (11.8 ng/mL), (5.2 ng/mL), and (1.5 ng/mL), respectively; and (799.6 ng/mL), (691.6 ng/mL), and (0.03 ng/mL), respectively. As regards vital signs in the two groups, MIS-C patients had significantly higher temperature, and oxygen saturation with (38.45 °C vs. 37.70 °C), and (98.48% vs. 95.32%), respectively. Regarding laboratory investigations, Ferritin, and CRP, MIS-C group had significantly higher values with (743 vs 290 µg/L), and (188, and 38), respectively. As regards correlation between Pentraxin 3 (PTX3), and Procalcitonin (PCT) with symptoms and laboratory investigations in the MIS-C group, PTX3 showed significant positive correlation with dehydration, hypotension, and creatinine level, (R = 0.108, 0.128, and 0.106), and (P = 0.001, 0.022, and 0.048), respectively. While Procalcitonin (PCT) showed significant positive correlation with dehydration, and Sequential Organ Failure Assessment (SOFA score) (R = 0.439, and 0.4), and (P = 0.036, and 0.032), respectively, in addition, it showed significant negative correlation with EF% (R=-0.511), and (P = 0.005). Regarding correlation between Pentraxin 3 (PTX3), and Procalcitonin (PCT) with symptoms and laboratory investigations in the Covid-19 group, they both had positive correlation duration of fever (R = 0.433, and 0.108), and (P = 0.021, and 0.585). On the other hand, oxygen saturation demonstrated an inverse correlation with Procalcitonin R=-0.376), and (P = 0.049), but not with Pentraxin 3. Conclusion it’s concluded that PTX3, and PCT levels significantly increase in Covid-19 patients, and MIS-C patients. Not only that, but they are significantly higher in the Covid-19 group than the MIS-C group.

Pentraxin-3 marker as a predictor of cardiovascular events in obstructive sleep apnea; a cross-sectional study

Introduction A large population suffers from obstructive sleep apnea (OSA). Most of these individuals (almost 90%) are either unrecognized or untreated OSA. These patients are at increased risk of cardiovascular diseases. Aim The aim of this study was to assess the prognostic value of Pentraxin 3 (PTX3) in OSA compared with the clinically relevant biological markers (HbA1c, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), uric acid, and fibrinogen) and to evaluate the relationship between PTX3 levels and risk of cardiovascular diseases. Patients and methods This research used a cross-sectional design and enrolled 100 participants with suspected OSA. All the participants underwent a full clinical history, a STOP-Bang questionnaire, and a polysomnography (PSG) study, and the serum biomarkers were also analyzed. Results The apnea-hypopnea index (AHI) from PSG was used to measure the OSA severity, and the individuals were distributed into three groups accordingly. Our findings showed that there was a significant difference in Pentraxin 3 and fibrinogen levels between patients with mild or moderate OSA and those with severe OSA. Pentraxin 3, at a cutoff point of greater than 4.25 ng/ml, had the highest prognostic accuracy in OSA (96%), with an AUC of 0.96. Regression analysis revealed that Pentraxin 3, with a cutoff point greater than 4.25, and CRP were significant predictors of cardiovascular disease in individuals with OSA. Furthermore, Pentraxin 3 (with a cutoff point of greater than 4.25 ng/ml) and fibrinogen were significant predictors of pulmonary embolism in patients with OSA. Conclusion Serum PTX3 was higher in patients with severe OSA than in those with mild- to moderate OSA. Furthermore, we found that OSA severity as indicated by the AHI was significantly correlated with serum PTX3. PTX3 and CRP are useful markers of cardiovascular risk in OSA.

The utility of pentraxin 3 and platelet-derived growth factor receptor beta as non-invasive biomarkers for prediction of cardiovascular risk in MAFLD patients

BackgroundMetabolic-associated fatty liver disease (MAFLD) has emerged as the predominant form of chronic liver disease globally linked with heightened cardiovascular disease (CVD) risk, the leading cause of mortality among affected individuals.AimThis study aims to assess serum PTX3 (pentraxin 3) and platelet-derived growth factor receptor beta (PDGFRβ) as potential non-invasive biomarkers for predicting cardiovascular risk (CVR) in MAFLD patients.MethodA case–control investigation encompassing 84 MAFLD patients without prior CVD history and 30 age- and gender-matched healthy controls was conducted. Both cohorts underwent comprehensive laboratory and radiological evaluations. CVR was evaluated through common carotid artery intima-media thickness (IMT), Framingham risk score, and QRISK 2 score. The efficacy of two ELISA biomarkers PTX3 and PDGFRβ was examined for correlation with CVR in MAFLD patients.ResultsMAFLD patients displayed significantly heightened levels of PTX3 and PDGFβ compared to healthy controls (P < 0.001, P = 0.016, respectively). PDGFβ exhibited a notably positive correlation with the Framingham score (P = 0.016), while no significant correlation was observed with pentraxin 3 (P = 0.061). Univariate and multivariate analyses identified diabetes mellitus (DM) (P < 0.001*), hypertension (P = 0.005), visceral fat (P < 0.001*), waist/hip circumference (P = 0.04), and PDGFβ (P = 0.03) as robust predictors of CVR, with PTX3 demonstrating limited prognostic utility.ConclusionPDGFβ emerged as a promising early non-invasive predictor of CVR in MAFLD patients, highlighting its potential role in guiding tailored preventive interventions, while PTX3 exhibited a modest impact warranting further investigation.

Serum pentraxin-3 in patients with chronic obstructive pulmonary disease: A meta-analysis.

The association between serum pentraxin-3 (PTX-3) levels and chronic obstructive pulmonary disease (COPD) has been explored in several studies. However, the results remain inconsistent. This meta-analysis aims to evaluate the differences in serum PTX-3 levels between COPD patients and healthy controls, as well as between patients with acute exacerbations of COPD (AECOPD) and stable COPD. Databases including PubMed, Embase, Web of Science, Wanfang, and China National Knowledge Infrastructure (CNKI) were systematically searched. A random-effects model was used to pool the results, accounting for the potential impact of heterogeneity. Subgroup and meta-regression analyses were performed to evaluate the influence of study characteristics on the outcome. The initial search identified 274 articles, with 17 studies meeting the inclusion criteria. These studies included a total of 996 AECOPD patients, 1414 stable COPD patients, and 1016 healthy controls. The meta-analysis showed significantly higher serum PTX-3 levels in COPD patients compared to healthy controls (standardized mean difference [SMD]: 0.51, 95% confidence interval [CI]: 0.30 to 0.73, P < 0.001; I² = 85%). Subgroup and meta-regression analyses suggested that the results were not significantly affected by the age, sex, or smoking status of the patients. Additionally, serum PTX-3 levels were higher in AECOPD patients compared to stable COPD patients (SMD: 0.58, 95% CI: 0.41 to 0.74, P < 0.001; I² = 59%). In conclusion, serum PTX-3 levels are elevated in COPD patients, particularly during acute exacerbations, compared to stable COPD patients and healthy controls. PTX-3 may serve as a potential biomarker for COPD severity and exacerbation status.

The Impact of Organized Exercise and Non-organized Leisured Time Activity on Serum Pentraxin3 and C-reactive Protein Levels, Lipid Profile and Physical Fitness in Diabetic Children

Background: Microvascular changes and precursors of atherosclerosis are frequently observed in young patients with early-onset type 1 diabetes (T1DM). Due to their known beneficial effects, physical activity is strongly recommended for its management. Objectives: This study aimed to investigate the effects of eight weeks of organized exercise (OE) and non-organized leisure time activity (NOLTA) on determinants of cardiovascular disease and physical fitness in children with type 1 diabetes. Methods: In this quasi-experimental study, 20 children with T1DM were randomly divided into two groups of 10: OE (n = 10, mean age = 12.60 ± 1.34 years) and NOLTA (n = 10, mean age = 12.40 ± 0.84 years). Subjects in both groups participated in their respective activities 3 days per week. Blood samples and physiological measurements were taken 48 hours before and after the 8-week training period. Results: High-density lipoprotein (HDL) levels and physical fitness factors increased significantly in both exercise groups. Fasting blood glucose, C-reactive protein, and the cholesterol/HDL ratio were also significantly reduced in both groups. Waist circumference, glycosylated hemoglobin, and the LDL/HDL ratio were significantly reduced only in the OE group. However, the decrease in the acute phase protein pentraxin 3 was minimal and statistically insignificant. Conclusions: In children and adolescents with T1DM, regular exercise—due to its anti-inflammatory effects and its ability to improve cardiorespiratory fitness, lipid profile, and blood glucose levels—may help reduce the severity and likelihood of cardiovascular disease in adulthood.

Prognostic Value of Pentraxin 3 and Procalcitonin in Late onset Neonatal Sepsis

Abstract Background Sepsis is a major cause of intensive care unit (ICU) admission. Procalcitonin (PCT) could be an important prognostic marker for sepsis. Pentraxin 3 (PTX3) and PCT are detectable in patients with sepsis within a large time window after the onset of sepsis. Objective To assess the prognostic value of the PTX3, PCT in neonatal sepsis in comparison with other sepsis screen. Patients and Methods A prospective study included 40 neonates with sepsis. The study had been conducted in the neonatal intensive care units of Ain Shams University, Children’s Hospital during the period from January 2020 to May 2022. All neonates had been subjected to clinical examination, anthropometric measurements and sepsis scoring by neonatal sequential organ failure assessment (nSOFA). Laboratory investigations were collected from all pediatrics including Complete blood count (CBC), quantitative C- reactive protein (CRP), blood culture, serum pentraxin 3 (PTX3) and serum procalcitonin (PCT). Sepsis markers had been obtained from neonates at the day of being with suspected sepsis before starting the antimicrobial therapy (Day 0). While blood samples for sepsis markers reobtained only from neonates with positive blood cultures on the 3rd (Day3), accordingly our patients divided into improved and deteriorated groups. Results There was a significant decrease in CRP level and increase in procalcitonin and pentraxin 3 levels in deteriorated group than improved group at baseline with p-value = 0.004, 0.016 and 0.019; respectively. Also, the study shows that there was a significant increase in CRP, procalcitonin and pentraxin 3 levels in deteriorated group than improved group after 3 days with p-value = 0.002, &amp;lt;0.001 and &amp;lt;0.001; respectively. Furthermore, in improved group, there was a significant decrease in the level of CRP, procalcitonin and pentraxin 3 after 3 days than at baseline with p-value = 0.001, &amp;lt;0.001 and 0.001; respectively. Also in deteriorated group, there was statistically significant increase in the CRP and pentraxin 3 levels after 3 days than at baseline in deteriorated group with p- value = 0.002 and 0.019; respectively while no change found in procalcitonin level. Conclusion Serum pentraxin 3 and procalcitonin levels seem to be promising prognostic markers in neonatal sepsis with higher sensitivity and specificity for procalcitonin than pentraxin at 3 days.

Effects of a medium cut-off dialyzer on inflammation and cardiac and vascular function in hemodialysis patients with heart failure.

Expanded hemodialysis (HDx) could provide clearance of larger middle-molecule uremic toxins. We compared the effect of hemodialysis with medium cut-off membranes and high-flux (HFHD) membranes regarding changes in inflammation and vascular and left ventricular function. This was a single-center, prospective, parallel-group comparative study. Patients were divided into two groups (HDx: 25 patients and HFHD: 26 patients). All measurements were performed at baseline and 12 weeks. Serum c-reactive protein, interkelukin-18, pentraxin-3, β-2 microglobulin, and brain natriuretic peptide were measured. We used pulse wave velocity and augmentation index to assess arterial stiffness and echocardiography to evaluate left and right ventricular function. We enrolled 51 patients. Although serum c-reactive protein, interkelukin-18, pentraxin 3, and β-2 microglobulin were significantly decreased in the HDx group (p = 0.02, p < 0.001, p = 0.002, and p = 0.02, respectively), there was no significant change in HFHD group at 12th week. Serum c-reactive protein and interkelukin-18were significantly lower in the HDx group compared to the HFHD group in the 12th week (p = 0.007 and p = 0.03, respectively). We observed a significant decrease in pulse wave velocity in the HDx group at the end of the study (p = 0.03). Although there was no significant change in pulse wave velocity in the HFHD group, pulse wave velocity was similar between the HDx and HFHD groups in the 12th week. We detected a significant decrease in the mean isovolumetric relaxation time in the HDx group (p = 0.006). However, there was no significant difference in isovolumetric relaxation time between the HDx and HFHD groups in the 12th week. HDx provides better clearance of middle molecular uremic toxins and inflammatory biomarkers, and it may be associated with better central hemodynamic parameters and diastolic functions.

Longitudinal soluble marker profiles reveal strong association between cytokine storms resulting from macrophage activation and disease severity in COVID-19 disease

SARS-CoV2 infection results in a range of disease severities, but the underlying differential pathogenesis is still not completely understood. At presentation it remains difficult to estimate and predict severity, in particular, identify individuals at greatest risk of progression towards the most severe disease-states. Here we used advanced models with circulating serum analytes as variables in combination with daily assessment of disease severity using the SCODA-score, not only at single time points but also during the course of disease, to correlate analyte levels and disease severity. We identified a remarkably strong pro-inflammatory cytokine/chemokine profile with high levels for sCD163, CCL20, HGF, CHintinase3like1 and Pentraxin3 in serum which correlated with COVID-19 disease severity and overall outcome. Although precise analyte levels differed, resulting biomarker profiles were highly similar at early and late disease stages, and even during convalescence similar biomarkers were elevated and further included CXCL3, CXCL6 and Osteopontin. Taken together, strong pro-inflammatory marker profiles were identified in patients with COVID-19 disease which correlated with overall outcome and disease severity.

The potential diagnostic value of serum pentraxin-3 in hepatocellular carcinoma in Egyptian patients

Background and aimHepatocellular carcinoma (HCC) is considered one of the most common cancers in the world and one of the principal causes of cancer-linked deaths. Therefore, identification of new biomarkers for diagnosis, especially early diagnosis of HCC, is very important. Pentraxin 3 (PTX3) is possibly involved in cancer development, and as regard to liver diseases, plasma PTX3 was implicated to be associated with HCC occurrence. Therefore, this study will determine the serum PTX3 levels in patients with cirrhosis and HCC and to assess the potential diagnostic value in HCC in Egyptian patients.ResultsPentraxin 3 was significantly higher in HCC patients than in cirrhotic patients (p < 0.001); also, serum PTX3 was significantly correlated with number, size of focal lesions, the presence of portal vein thrombosis, and BCLC staging (p < 0.001).ConclusionThe significant increased levels of serum pentraxin 3 in HCC may support its use as an early marker for HCC, either alone or in combination with serum alpha-fetoprotein (AFP), allowing early diagnosis and prompt intervention.

Comparison of Pentraxin-3 in Migraine Patients without Aura and Healthy Controls

Background and Objectives: Migraine is a common cerebrovascular condition marked by one-sided, pulsating headache, which may or may not be accompanied with an aura. Migraine is mostly found in females who are of childbearing age. One of the speculated mechanisms for the pathophysiology of migraine is endothelial dysfunction. A new biomarker of inflammatory disorders, pentraxin-3 is often produced by endothelium injury. In earlier investigations, it was shown that migraine sufferers had elevated levels of pentraxin-3. Our study's objectives were to analyze the serum pentraxin-3 levels in migraine sufferers without aura and healthy controls.Methods: It was a cross-sectional comparative study. This was done at the IMBB Department, University of Lahore, Lahore Pakistan, from March 2020 to April 2022. We took 40 diagnosed migraine cases and 40 healthy controls. Detailed examination was done and proformas were filled by both cases and controls. Serum was collected by each of them and pentraxin-3 values were determined by using specific Elisa kits. SPSS version 22 was used for statistical analysis. For normality of data Shapiro wilk test was used. Mann whiteny U test was used for the comparision of means of pentraxin-3 in migrainers and healthy controls.Results: The data were non-normally distributed after the Shapiro-Wilk Test. The average age of the controls was 25±6.06 years, while that of individuals with migraines was 26±7.78 years. Patients with migraine were mostly women. The majority of the patients had BMI category 18 to 24.5. Patients with migraine had mean pentraxin-3 levels of 145.75 ±157.7 pg/l, compared to 43.65 ±33.01 pg/l in the control group. Median was100.5 in cases and 31.15 in controls. P-value was 0.0001.Conclusion: When compared to the control group, migraine patients had considerably higher blood levels of PTX-3, and no correlations between age, BMI, marital status, smoking history, and usage of preventative medications were found.Key words: migraine, pentraxin-3, endothelial dysfunction, C-reactive protein (CRP),

Diagnostic significance of serum pentraxin 3 concentration in colorectal cancer patients

Diagnostic significance of serum pentraxin 3 concentration in colorectal cancer patients

The correlation between pentraxin-3, matrix metalloproteinase-9, and estimated glomerular filtration rate in patients with chronic kidney disease

Background: Chronic kidney disease (CKD) is diagnosed when there is a sustained decrease in the estimated glomerular filtration rate (EGFR) over a period of more than 3 months. While Pentraxin-3 (PTX-3) and Matrix Metalloproteinase-9 (MMP-9) levels increase during the acute phase of the kidney injury, chronic conditions often exhibit alteration in the epithelial mesenchymal transition (EMT).Objectives: This study aimed to elucidate the correlation between serum PTX-3, MMP-9, and eGFR in patients with CKD. Method: Thirty hypertensive patients with CKD stages 3, 4, and 5, aged between 16 and 65 years, were enrolled in the study (15 males and 15 females). Diagnosis of CKD was based on the 2012 Kidney Disease Improving Global Outcomes (KDIGO) criteria, utilizing serum creatinine, and CKD-epidemiology Collaboration (CKD-EPI) estimates. Subsequently, serum MMP-9 and PTX-3 levels were quantified. Result: Patients with CKD exhibited significantly higher serum levels of PTX3 and MMP9. Furthermore. a significant negative connection between PTX-3, MMP-9, and EGFR was observed. Additionally, CKD patients displayed a correlation between PTX-3 and MMP-9 concentrations.Conclusion: Plasma levels of PTX-3 and MMP-9 serve as unique, promising, and important markers that contribute to the pathogenesis of CKD.

Serum Pentraxin 3 as a Biomarker of Hepatocellular Carcinoma in Egyptian Liver Cirrhotic Patients

Serum Pentraxin 3 as a Biomarker of Hepatocellular Carcinoma in Egyptian Liver Cirrhotic Patients

Role of serum pentraxin-3 levels in patients with and without diabetic nephropathy

Role of serum pentraxin-3 levels in patients with and without diabetic nephropathy

Serum pentraxin 3 levels in term neonates with persistent pulmonary hypertension.

Persistent pulmonary hypertension of the neonate (PPHN) is a serious disorder. The long pentraxin 3 (PTX3) plays an important role in angiogenesis, cell proliferation, tissue repair and cell regulation. The present study aims to assess the diagnostic and clinical value of PTX3 in PPHN. The present case-control 60 full-term neonates diagnosed with PPHN by echocardiography within 72 hours of birth. In addition, there were 30 age and sex-matched healthy neonates who served as controls. All participants were subjected to careful history taking and complete clinical examination, Laboratory investigations included complete blood count, C-reactive protein (CRP), blood culture and PTX3 level. Radiological investigations included plain X- ray and two-dimensional transthoracic echocardiography (TTE). Comparison between patients and controls revealed that patients had significantly higher CRP (6.12±2.18 versus 3.69±1.25 mg/dl, p<0.001) and PTX3 levels (2.07±0.67 versus 0.96±0.21, p<0.001) when compared with controls. Patients with associated PDA had significantly higher PTX3 levels when compared with patients without (2.58±0.5 versus 2.02±0.51 ng/ml, p = 0.002). Also, patients with associated PFO had significantly higher PTX3 levels when compared with patients without (2.12±1.05 versus 2.05±0.46, p = 0.002). ROC curve analysis identified good performance of CRP and PTX3 levels in diagnosis of PPHN with PTX3 showing better performance. There is a significant association between serum PTX3 levels and PPHN particularly those with associated PDA or PFO.

Effects of Spirulina supplementation in patients with ulcerative colitis: a double-blind, placebo-controlled randomized trial

AimWe conducted a randomized placebo-controlled trial to assess the efficacy of Spirulina (SP) supplementation on disease activity, health-related quality of life, antioxidant status, and serum pentraxin 3 (PTX-3) levels in patients with ulcerative colitis (UC).MethodsEighty patients with UC were randomly assigned to consume either 1 g/day (two 500 mg capsules/day) of SP (n = 40) or control (n = 40) for 8 weeks. Dietary intakes, physical activity, disease activity, health-related quality of life, antioxidant status, erythrocyte sedimentation rate (ESR), and serum PTX-3 levels were assessed and compared between groups at baseline and post-intervention.ResultsSeventy-three patients (91.3%) completed the trial. We observed increases in serum total antioxidant capacity levels in the SP supplementation group compared to the control group after 8 weeks of intervention (p ≤ 0.001). A within-group comparison indicated a trend towards a higher health-related quality of life score after 8 weeks of taking two different supplements, SP (p < 0.001) and PL (p = 0.012), respectively. However, there were no significant changes in participant’s disease activity score in response to SP administration (p > 0.05). Similarly, changes in ESR and PTX-3 levels were comparable between groups post-intervention (p > 0.05).ConclusionsSP improved antioxidant capacity status and health-related quality of life in patients with UC. Our findings suggest that SP supplementation may be effective as an adjuvant treatment for managing patients with UC. Larger trials with longer interventions periods are required to confirm our findings.